Co-Diagnostics

Co-Diagnostics Net Change in Cash

The Net Change in Cash of Co-Diagnostics (CODX) as of Nov 20, 2026 is 8.95 M USD. In the previous year, Net Change in Cash was -11.98 M USD — a change of -174.69% (higher).

Net Change in Cash

8.95 MUSD

YoY

-174.69%

Last updated:

Net Change in Cash of Co-Diagnostics is 2025 8.95 M USD. Net Change in Cash of Co-Diagnostics was 2024 -11.98 M USD. It decreases by -174.69% higher compared to the previous year.

The Co-Diagnostics Net Change in Cash history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Change in Cash
Date
Net Change in Cash
Jan 1, 2018
-2.58 M USD
Jan 1, 2019
-57,099.00 USD
Jan 1, 2020
42.08 M USD
Jan 1, 2021
45.63 M USD
Jan 1, 2022
-65.63 M USD
Jan 1, 2023
-8.06 M USD
Jan 1, 2024
-11.98 M USD
Jan 1, 2025
8.95 M USD
The Co-Diagnostics Net Change in Cash history
YEARNet Change in CashYoY
8.95 MUSD-174.69%
-11.98 MUSD+48.70%
-8.06 MUSD-87.72%
-65.63 MUSD-243.84%
45.63 MUSD+8.43%
42.08 MUSD-73,802.82%
-57,099.00USD-97.79%
-2.58 MUSD-201.91%
2.54 MUSD+162.79%
964,932.00USD-634.17%
-180,641.00USD-625.09%
34,402.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Co-Diagnostics Stock analysis

What does Co-Diagnostics do? Co-Diagnostics, Inc. develops and sells diagnostic tests using proprietary reagents and a test design system for diseases and pathogens including tuberculosis, drug-resistant tuberculosis, hepatitis B and C, malaria, dengue, HIV, and Zika virus. The company also markets self-contained lab systems (MDx devices) from other manufacturers. Its products are sold to laboratories and healthcare providers for molecular testing of organisms and genetic diseases, automating complex procedures in test development and administration. The firm generates revenue through the sale of diagnostic reagents, validated tests, and MDx devices. The company's diagnostic technology focuses on nucleic acid detection and analysis, enabling molecular testing for various pathogens and genetic conditions. Its proprietary system allows for the design and validation of tests in-house, which are then marketed to healthcare institutions. Revenue streams include reagent sales, test kits, and equipment from partner manufacturers. Co-Diagnostics, Inc. targets laboratories and healthcare providers as key customers for its diagnostic solutions. The firm's products are designed to streamline molecular testing processes, reducing the complexity of traditional methods. This approach supports the company's revenue model based on direct sales of its proprietary tests and complementary equipment. Co-Diagnostics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Co-Diagnostics stock

Net Change in Cash of Co-Diagnostics is 8.95 M USD in 2025.

Net Change in Cash of Co-Diagnostics changed from -11.98 M USD to 8.95 M USD, representing a -174.69% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Change in Cash Co-Diagnostics since 2006 – with annual values, charts, and detailed analysis.

Net change in cash is the total change in cash and equivalents during the period, combining operating, investing, and financing cash flows.

Net Change in Cash's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Change in Cash's Co-Diagnostics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Co-Diagnostics

All Key Metrics — Co-Diagnostics